Liang Peng, MD, PHD
Titles
Professor
Doctoral Supervisor
Department of Infectious Diseases
Research Interests
1. Treatment of hepatitis, including anti-viral therapy, artificial liver support system and stem cells transplantation.
2. Treatment of liver diseases and infectious diseases.
3. Genetics mechanism in HBV infection.
4. Proteomics mechanism in HBV infection.
Education and Experience
2013-2014 Post-doctoral training in Hôpital Beaujon, University Paris-Diderot, France.
2007 Doctoral degree, the Sun Yat-sen University, Doctoral thesis: “Application of stem cells in liver diseases” and “Clinical and mechanism research of liver failure with Hepatitis B”
2004 Master’s degree, Guiyang Medical School, Master thesis: “Study of HBV genotype”.
1998-2001 Residency, Department of Infectious Diseases, Xiangya Hospital.
1998 Bachelor’s degree, School of Medicine, Central-South University, Xiangya.
Honors and Awards
l “Mechanism research of more susceptibility to HBV infection induced by mutation IFNA2 p.Ala120Thr”, the National Natural Science Foundation of China, 2016-2019, head of the program.
l “Mechanism research of transmembrane protein TMEM2 in the HBV infection into cells”, the National Natural Science Foundation of China, 2014-2017, head of the program.
l “Analysis of serum protein from hepatitis B patients and researches of their effects on Th17/ Treg cells as biomaker”, the National Natural Science Foundation of China, 2012-2014, head of the program.
l “Agnoprotein identification and analysis of function on MSCs in serum from liver failure rats”, Natural Science Foundation of Guangdong Province of China, 2009-2011, head of the program.
l “Absence protein identification and analysis of function on MSCs in liver homogenate from liver failure rats”, Ph.D. Programs Foundation of Ministry of Education of China, 2010-2012, head of the program.
l “Study of effects of transmembrane protein TMEM2 in the HBV infection”, the Fundamental Research Funds for the Central Universities, 2012.11-2015.11, head of the program.
Publications
1、Liu R, Chen C, Xia X, Liao Q, Wang Q, Newcombe PJ, Xu S, Chen M, Ding Y, Li X, Liao Z, Li F, Du M, Huang H, Dong R, Deng W, Wang Y, Zeng B, Pan Q, Jiang D, Zeng H, Sham P, Cao Y, Maxwell PH, Gao ZL*, Peng L*(co-corresponding author), Wang Y*. Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine. Scientific Reports. 2017 Aug 23;7(1):9214. doi: 10.1038/s41598-017-07012-2. (2016 IF = 4.2589)
2、Ying L, Cheng H, Xiong XW, Yuan L, Peng ZH, Wen ZW, Ka LJ, Xiao X, Jing C, Qian TY, Liang GZ, Mei YG, Bo ZW, Liang P*. Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. Oncotarget. 2017 Apr 11;8(15):24694-24705. (2016 IF = 5.168)
3、Qiyi Zhao*, Geng-lin Zhang, Xiang Zhu, Di Su, Zhan-lian Huang, Zhao-xia Hu, Liang Peng* (co-corresponding author). The paradoxical changes of membrane and soluble herpes virus entry mediator in hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2017 Aug;32(8):1520-1524. (2015 IF = 3.322)
4、Zhang GL, Zhang T, Ye YN, Liu J, Zhang XH, Xie C, Peng L* (co-corresponding author), Gao ZL*. Complement Factor 3 Could Be an Independent Risk Factor for Mortality in Patients with HBV Related Acute-on-Chronic Liver Failure. Biomed Res Int. 2016;2016:3524842. doi: 10.1155/2016/3524842. Epub 2016 Apr 6. (2015 IF = 2.13)
5、Zhu X, Xie C (co-first author), Li YM, Huang ZL, Zhao QY, Hu ZX, Wang PP, Gu YR, Gao ZL, Peng L*. TMEM2 inhibits hepatitis B virus infection in HepG2 and HepG2.2.15 cells by activating the JAK-STAT signaling pathway. Cell Death & Disease. 2016 Jun 2;7(6):e2239. doi: 10.1038/cddis.2016.146. (2016 IF = 5.965)
6、Liang Peng, Qiang Zhao, Qibin Li, Miaoxin Li, Caixia Li,Tingting Xu,Xiangyi Jing, Xiang Zhu, Ye Wang, Fucheng Li, Ruihong Liu, Cheng Zhong, Qihao Pan, Binghui Zeng, Qijun Liao, Bin Hu, Zhao-xia Hu, Yang-su Huang, Pak Sham, Jinsong Liu, Shuhua Xu, Jun Wang*, Zhi-liang Gao*, Yiming Wang*. The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology, 2015, 61(4): 1251–1260. doi: 10.1002/hep.27608. (2014 IF = 11.19)
7、Liang Peng, Jing Liu, Yang-mei Li, Zhan-lian Huang, Pei-pei Wang, Yu-bao Zheng, Yun-peng Hua, Zhi-liang Gao. iTRAQ-based proteomic analysis of hepatic tissues from patients with HBV-induced acute on chronic liver failure ( ACLF ). EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10: 1732-1742. (2014 IF = 1.269)
8、Liang Peng, Jing Liu, Yang‑Mei Li, Zhan‑Lian Huang, Pei‑Pei Wang,YU‑Rong Gu, Yu‑Bao Zheng and Zhi‑Liang Gao. Serum proteomics analysis and comparisons using iTRAQ in the progression of hepatitis B. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6: 1169-1176. (2014 IF = 1.269)
9、Qiang Zhao , Liang Peng (co-first author), Weijun Huang, Qibin Li, Yuanyuan Pei, Ping Yuan, Lingyan Zheng, Yongling Zhang, Jia Deng, Cheng Zhong, Bin Hu, Hongke Ding, Wei Fang, Ru Li, Qijun Liao, Chaoshuang Lin, Weiping Deng, Huijun Yan, JinghuiHou, Qiuliang Wu, Tingting Xu, Jinsong Liu, Longbo Hu, Tao Peng, Suqing Chen, Kar N. Lai, Man-Fung Yuen, Yue Wang, Mala K. Maini, Caixia Li, Miaoxin Li, Jian Wang, Xiuqing Zhang, Pak-Chung Sham, Jun Wang*, Zhi-Liang Gao*, and Yiming Wang*. Rare inborn errors associated with chronic hepatitis B virus infection. Hepatology, 2012,56(5): 1661-1670. (2012 IF = 12.003)
10、Liang Peng, Dong-ying Xie, Bing-liang Lin, Jing Liu, Hai-peng Zhu, Chan Xie, Yu-bao Zheng, Zhiliang Gao, et al. Autologous bone mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-trm outcomes. Hepatology, 2011,54(3): 820-828. (2011 IF = 10.885)
Contact
Department of Infectious Diseases
The 3rd Affiliated Hospital of Sun Yat-sen University.
600# Tianhe Road, Guangzhou, China
Phone: 86-20-85252372
Mobil Phone: 86-13533978874
Fax: 86-20-85252250
